Particularly, significant downregulation of the CPS1 gene was found in ovarian tumors after the treatment with combinations of 9 mg/kg paclitaxel with 1 mg/kg SB-T-121606 (Group V; p = 0.004) and 7 mg/kg paclitaxel with 3 mg/kg SB-T-121606 (Group VI; p < 0.001) compared to paclitaxel alone (Group II, Figure 5A). Here, CPS1 is linked to ovarian neoplasm.